1 **High Prevalence and Genotypic Diversity of Persistent *Chlamydia trachomatis***

2 **Infections Among South African Adolescent Girls and Young Women: A Tale of Two**

3 **Cities**

Smritee Dabee,[1,2] Shaun Barnabas,[1,3] Bart Versteeg,[4] Brian Kullin,[1,2] Shameem Z.

Jaumdally,[1] Hoyam Gamieldien,[1,2] Nonhlanhla Mkhize,[5] Etienne Muller,[5] Venessa Maseko,[5]

Katherine Gill,[1,3] Darren P. Martin,[1] Glenda Gray,[6,7] Linda-Gail Bekker[1,3] David A. Lewis,[8,9]

Heather B. Jaspan,[1,10] Sylvia M. Bruisten,[11,12] Jo-Ann S. Passmore[1,2,13#]

[1]Institute of Infectious Disease and Molecular Medicine (IDM), Division of Medical Virology, Dept. Pathology,

University of Cape Town, Cape Town, South Africa; [2]DST-NRF CAPRISA Centre of Excellence in HIV

Prevention, University of Cape Town, Cape Town, South Africa; [3]Desmond Tutu HIV Centre, University of

Cape Town, South Africa; [4]Knowledge institute of the Dutch association of Medical Specialists, Utrecht,

Netherlands; [5]Centre for HIV and STIs, National Institute for Communicable Disease, National Health

Laboratory Service, South Africa; [6]Perinatal HIV Research Unit, Faculty of Health Sciences, University of the

Witwatersrand, Diepkloof, Johannesburg, South Africa; [7]South African Medical Research Council, Cape Town,

South Africa; [8]Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta,

Australia; [9]Sydney Infectious Diseases Institute & Sydney Medical School-Westmead, University of Sydney,

Sydney, Australia; [10]Seattle Children's Research Institute, University of Washington, Seattle, Washington,

USA; [11]Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands;

[12]Amsterdam Infection and Immunity Institute, Academic Medical Center, University of Amsterdam,

Amsterdam, the Netherlands; [13]National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South

Africa

#Address correspondence to Professor Jo-Ann S. Passmore, Institute of Infectious Disease and Molecular

Medicine, University of Cape Town, Medical School, Anzio Road, Observatory, 7925 Cape Town, South

Africa. E-mail: Jo-ann.Passmore@uct.ac.za, Tel: +21-21-6507963

Word count: 1930, Abstract (95), Figures: 2, Supplementary Tables: 1

Running title: Chlamydia Genotypic Diversity in South Africa

Abstract

Chlamydia trachomatis (CT) is the most common sexually transmitted bacterial infection

globally, significantly affecting adolescent girls and young women (AGYW) in South Africa.

This study investigated CT prevalence and genotypic diversity among 298 AGYW from

Cape Town and Johannesburg, revealing an overall prevalence of 29.5%. Prevalence was

higher in Cape Town (41.6%) compared to Johannesburg (17.4%; p<0.0001). Genetic

analysis identified 34 sequence types, including 15 novel variants. Longitudinal data

highlighted frequent reinfections or persistent infections despite treatment. These findings

underscore the importance of addressing CT's genetic diversity for improved reproductive

health strategies and vaccine development.

Words: 100

Keywords: South Africa, Adolescent, female, genital, STIs, Chlamydia trachomatis,

genotype, MLST

Introduction

Adolescent girls and young women (AGYW) in sub-Saharan Africa are at heightened risk for sexually transmitted infections (STIs), including *Chlamydia trachomatis* (CT), which exacerbates HIV acquisition risks and reproductive complications (1). The asymptomatic nature of most CT infections in women complicates diagnosis and management (2), necessitating a deeper understanding of its epidemiology and genotypic diversity. South Africa's geographic diversity in sociocultural practices, healthcare access, and STI prevalence underscores the importance of studying CT genotypes across different regions (3). Across South Africa, there are significant regional variations in CT prevalence and associated complications (4), which may be influenced by differences in circulating genotypes, some of which may be associated with enhanced inflammatory responses, persistence, or increased risk of complications (5).

Here we characterise CT genotypes among AGYW from two urban South African settings (Cape Town and Johannesburg) using high resolution multi-locus sequence typing (MLST) to further explore regional differences in the prevalence of different CT genetic variants (6). Besides enabling the identification of novel sequence types (STs), MLST data are useful for tracking the circulation of different genetic variants over time and across geographical regions. These data align with South Africa's genomic surveillance goals, which could be extremely valuable for monitoring the emergence and spread of pathogenic or treatment-resistant CT strains (7).

At the level of individual participants, MLST typing of CT variants is also useful in that it can (i) indicate whether epidemiologically linked patients experiencing recurrent infections are acquiring them from independent sources, and (ii) differentiate between unrelated new and persistent infections. This latter point is important as inadequately treated

CT infections can persist or recur, perpetuating inflammation and increasing the risk of long-

term complications.

Evaluating CT genotypes associated with AGYW from two geographically distinct

locations in South Africa addresses an important gap in our understanding of the interplay

between CT genetic diversity and regional epidemiological patterns of CT infections in this

country. Closing this gap will inform both general STI and HIV prevention strategies, and

the design of CT vaccines tailored to the needs of South African AGYW.

Materials and Methods

Cohort Description: This study recruited sexually active AGYW aged 16–22 years from two urban centres in South Africa: the Desmond Tutu Health Centre (DTHC) in Cape Town and the Perinatal HIV Research Unit (PHRU) in Johannesburg (4). Participants were excluded if they were living with HIV, pregnant, not sexually active, or if they had douched, used spermicides within the past two days, or taken antibiotics within the last two weeks. Visits for AGYW who were using injectable contraceptives, such as depot medroxyprogesterone acetate (DMPA) or norethisterone enanthate (Net-EN), were scheduled two weeks post-injection. For those not using injectable hormonal contraceptives, visits were aligned with the luteal phase of their menstrual cycle (days 14–28). Ethical approval was obtained from the Universities of Cape Town (UCT HREC #267/2013) and Witwatersrand Research Ethics Committees (WITS HREC #M130745). Written informed consent was provided by participants aged 18 years or older, while those under 18 years provided written assent alongside parental or guardian consent. At enrolment, participants completed a detailed socio-demographic questionnaire covering ethnicity, language, sexual orientation, reproductive health (e.g., contraceptive use, HIV/STI testing history, hygiene practices), and sexual behaviour (e.g., recent intercourse, condom use, and number of lifetime partners).

Sample Collection: During each clinical visit, a speculum examination was conducted. A

Dacron vulvovaginal swab was collected for STI testing and a lateral vaginal wall

FLOQSwab™ sample for preparing a Gram-stained slide for Nugent scoring to diagnose

bacterial vaginosis (BV) (4). Vulvovaginal swabs were analyzed for discharge-causing STIs,

including *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae*, *Trichomonas vaginalis*, and

Mycoplasma genitalium, as well as ulcerative STIs, such as HSV-1, HSV-2, *Haemophilus*

ducreyi, and *Treponema pallidum*, using real-time multiplex polymerase chain reaction

(PCR) assays. BV was categorized based on Nugent scoring: scores of 7–10 indicated BV

positivity, 4–6 were intermediate, and 0–3 were BV-negative. Participants with positive

results received treatment according to South African national guidelines, with a contact slip

being given as part of the care protocol (4).

Chlamydia MLST: The genotypic diversity of *C. trachomatis* was analyzed using MLST

and *ompA* genotyping (6) (7). Sequence data from five non-housekeeping gene loci (Uppsala

typing scheme) were analysed using the CT database hosted on PubMLST

(https://pubmlst.org/bigsdb?db=pubmlst_chlamydiales_seqdef). Allelic combinations that

were not present in the CT MLST database were assigned preliminary subtype (ST) numbers

(ST551-ST560). The *ompA* genovars were assigned by comparison to an offline reference

database described previously (6). BioEdit (http://www.mbio.ncsu.edu/bioedit/bioedit.html)

was used for sequence editing, with sequences assembled and aligned using the ClustalW

tool in MEGA4 (http://www.megasoftware.net/). Minimum-spanning trees were generated

using BioNumerics (Applied Maths, Sint-Martens-Latem, Belgium) to explore genetic

relationships between strains.

Results

A total of 298 sexually active AGYW from two communities — Cape Town (n=149) and Johannesburg (n=149) — were included in this study. Participants from Cape Town were followed longitudinally over three visits spanning 6–8 months, whereas those from Johannesburg were enrolled for a single visit (Supplementary Table 1; 5). Contraceptive use varied significantly between the sites. While all AGYW in Cape Town used contraception with the most common contraceptive type (105/149; 70.5%) being injectable Net-EN, in Johannesburg, 90.6% used contraception, with condoms being the most common type (77/149; 63.8%). As we have previously reported, the prevalence of treatable STIs in the cohort was notably high, affecting 74.2% of participants (221/298). Among these, 10.1% (30/298) had multiple concurrent STIs, and 37.2% (111/298) had both an STI and BV (4).

CT was the most prevalent STI in the study, affecting 88 of 298 participants (29.5%) at enrolment, with prevalence being higher in Cape Town (62/149; 41.6%) than Johannesburg (26/149; 17.4%; p<0.0001). All CT cases were asymptomatic (4). Younger adolescents were disproportionately affected, with a prevalence of 33.8% (69/204) among those aged 16–19 years, compared to 20.2% (19/94) in those aged 20–22 years (Chi-squared p=0.02). Among participants infected with CT, 71.6% (63/88) were co-infected with another STI or had BV (Nugent score 7–10), highlighting the high burden of co-occurring reproductive tract conditions in this population.

OmpA typing and MLST were performed on 128 samples with available DNA, including 20/26 cases from Johannesburg and 108/121 from Cape Town. Of these, 18 samples had either insufficient DNA or low bacterial loads. From these CT cases, 34 STs were identified by MLST, with 25/34 circulating in Cape Town and 12/34 in Johannesburg (Figure 1A). Of these, 15 were novel STs not previously reported. The three most common were ST12d (13.3%), ST530b (12%), and ST3 (9.3%). ST12d was the most common ST in

Cape Town but was absent in Johannesburg. ST530b was the most common ST in

Johannesburg. STs found in Johannesburg but not Cape Town included ST062a, ST086, and

ST560.

Despite demographic differences between Cape Town and Johannesburg, a minimum

spanning tree analysis revealed no clear clustering of genotypes by location (Figure 1B).

Based on sequences from *ompA*, CT genovars from Cape Town and Johannesburg largely

overlapped, with genovar E and D being common in both regions (Figure 1C). However,

certain notable differences were evident, with genovar F only being found in Cape Town and

genovar G being more common in Johannesburg than Cape Town.

In Cape Town, where adolescents were followed longitudinally, 33.9% who were

infected at visit 1, were infected with CT at visit 2, and 18.2% were infected at visit 3 (Figure

2A). Among these, 10 individuals tested positive for CT at all three study visits, 10 were

infected at the first two visits, and 5 were infected at visits 1 and 3 only. For those infected at

>1 study visit, the majority harboured the same ST across visits, suggesting persistent

infections or reinfection from the same source (Figure 2B).

Discussion

This study highlights the high prevalence, persistence, and genotypic diversity of CT

infections among AGYW in South Africa, a group disproportionately affected by STIs and

their associated adverse reproductive health outcomes. The findings emphasize the urgent

need for targeted interventions to address South Africa's significant chlamydial burden,

particularly its implications for HIV acquisition and complications like pelvic inflammatory

disease and infertility. CT prevalence in this cohort was 29.5%, with significant geographic

variation: 41.6% in Cape Town compared to 17.4% in Johannesburg. The higher prevalence

in Cape Town likely reflects differences in recruitment settings (reproductive health clinics

versus general populations) and contraceptive use patterns. All CT infections were

asymptomatic, underscoring the silent nature of these infections and the importance of

routine diagnostic screening (2). Younger AGYW (aged 16–19) were disproportionately

affected, emphasizing the need for early sexual health education and prevention programs.

Co-infections were prevalent, with 71.6% of CT-positive participants also diagnosed with

another STI or BV. This co-occurrence likely exacerbates genital inflammation, potentially

compromising mucosal barrier integrity and increasing susceptibility to HIV (8) and other

complications.

Genotypic analysis using MLST revealed significant genetic diversity with 34 STs

identified, including 15 novel STs. Regional differences were observed, with ST12d

predominant in Cape Town and ST530b in Johannesburg. The lack of geographical clustering

indicates widespread circulation of certain genotypes. Notably, whereas globally prevalent

ompA genovars such as D and E (5) were dominant in both the South African cities studied,

another globally dominant genotype, genovar F, was entirely absent in Johannesburg.

Genovar G, a less globally common but potentially more pathogenic genotype (5) (9), was

detected at a higher frequency in Johannesburg. Given that the infectiousness of CT is

significantly influenced by the *ompA* genotype of the infecting strain (10), these findings

underscore the importance of regional surveillance to identify locally relevant

epidemiological patterns with respect to informing tailored interventions (10) (5). The

identification of novel STs expands our understanding of the genetic diversity of CT and the

potential impact of this diversity on virulence, immune evasion, and disease progression.

Future studies should investigate the functional implications of these genotypic variations to

better understand their role in disease transmission and clinical outcomes.

Persistent or recurrent CT infections were common in the Cape Town cohort, where

participants were followed longitudinally. Among those with repeated infections, the same

ST was frequently identified across visits, indicating either reinfection from untreated

partners or incomplete clearance of infections. This calls attention to the importance of

partner notification, treatment, and test of cure to ensure resolution (4) in that persistent

infections likely contribute to sustained inflammation, which may exacerbate reproductive

health risks, including HIV susceptibility.

From a public health perspective, addressing the high burden of CT among young

women in South Africa requires a multifaceted approach. Although there has been a shift in

policy in some countries (like the Netherlands) around the need for ongoing STI screening

and treatment (11), these data from South Africa strongly argue that expanding access to

effective and affordable STI POC testing in regions with high HIV burden, integrating

partner notification systems, and promoting consistent condom usage are needed for

controlling CT infections.

These findings stress the need for vaccines targeting CT, particularly those tailored to

the most prevalent genotypes in high-burden regions (8). Collar and colleagues (5) present

compelling evidence emphasizing the necessity for CT vaccine strategies to account for

regional variations in CT genotypes. This approach is critical to ensuring that interventions

are not only effective but also equitable, addressing the unique epidemiological and genetic

diversity of CT across diverse communities. Genomic surveillance is set to play a pivotal role

in addressing CT burden (5). By providing detailed insights into genetic diversity and the

regional distribution of this diversity, persistent and coordinated genomic surveillance would

facilitate the near real-time identification of emerging variants and timely inform context-

specific interventions. Incorporating genetic diversity data into vaccine development

pipelines should also ensure broader protection against locally prevalent rather than just

globally dominant CT genotypes (5).

In conclusion, this study provides an analysis of the prevalence, persistence, and

genotypic diversity of CT among AGYW in South Africa. The findings emphasize the need

for targeted interventions to mitigate the health risks associated with CT. By integrating

genomic surveillance, public health initiatives, and community-based strategies, we can

address the multifaceted burden of CT and improve reproductive health outcomes for AGYW

in South Africa and beyond.

Acknowledgements

We extend our gratitude to the WISH study team, with special thanks to Ms. Penelope

Ngcobo for her efforts in participant recruitment and Sr. Janine Nixon. We are deeply

appreciative of the young women who participated in the study, without whom this research

would not have been possible.

Funding sources

This work was supported by the EDCTP Strategic Primer grant (SP.2011.41304.038; PI: J.

Passmore, UCT) and a self-initiated grant from the South African Medical Research Council

(PI: J. Passmore, UCT).

Conflict of Interest

All authors declare no conflicts of interest related to this work.

References

1.   Delany-Moretlwe S, Mgodi N, Bekker LG, Baeten JM, Li C, Donnell D, et al. High
prevalence and incidence of gonorrhoea and chlamydia in young women eligible for HIV
pre-exposure prophylaxis in South Africa and Zimbabwe: results from the HPTN 082
trial. Sex Transm Infect. 2023;99(7):433-9. Epub 20230308. doi: 10.1136/sextrans-
2022-055696. PubMed PMID: 36889914; PubMed Central PMCID: PMC10555488.
2.   Fortas C, Delarocque-Astagneau E, Randremanana RV, Crucitti T, Huynh BT.
Asymptomatic infections with Chlamydia trachomatis, Neisseria gonorrhoeae, and
Trichomonas vaginalis among women in low- and middle-income countries: A
systematic review and meta-analysis. PLOS Glob Public Health. 2024;4(5):e0003226.
Epub 20240523. doi: 10.1371/journal.pgph.0003226. PubMed PMID: 38781286;
PubMed Central PMCID: PMC11115196.
3.   Mkhize P, Mehou-Loko C, Maphumulo N, Radzey N, Abrahams AG, Sibeko S, et al.
Differences in HIV risk factors between South African adolescents and adult women and
their association with sexually transmitted infections. Sex Transm Infect. 2024. Epub
20241204. doi: 10.1136/sextrans-2024-056260. PubMed PMID: 39632075.
4.   Barnabas SL, Dabee S, Passmore JS, Jaspan HB, Lewis DA, Jaumdally SZ, et al.
Converging epidemics of sexually transmitted infections and bacterial vaginosis in
southern African female adolescents at risk of HIV. Int J STD AIDS. 2018;29(6):531-9.
Epub 20171204. doi: 10.1177/0956462417740487. PubMed PMID: 29198180.
5.   Collar AL, Clarke TN, Jamus AN, Frietze KM. Ensuring equity with pre-clinical
planning for chlamydia vaccines. NPJ Vaccines. 2023;8(1):131. Epub 20230906. doi:
10.1038/s41541-023-00726-7. PubMed PMID: 37673890; PubMed Central PMCID:
PMC10482967.
6.   Herrmann B, Isaksson J, Ryberg M, Tangrot J, Saleh I, Versteeg B, et al. Global
Multilocus Sequence Type Analysis of Chlamydia trachomatis Strains from 16 Countries.
J Clin Microbiol. 2015;53(7):2172-9. Epub 20150429. doi: 10.1128/JCM.00249-15.
PubMed PMID: 25926497; PubMed Central PMCID: PMC4473235.
7.   Bom RJ, Christerson L, Schim van der Loeff MF, Coutinho RA, Herrmann B,
Bruisten SM. Evaluation of high-resolution typing methods for Chlamydia trachomatis
in samples from heterosexual couples. J Clin Microbiol. 2011;49(8):2844-53. Epub
20110608. doi: 10.1128/JCM.00128-11. PubMed PMID: 21653758; PubMed Central
PMCID: PMC3147734.
8.   Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, et al.
Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis.
2015;61(2):260-9. Epub 20150421. doi: 10.1093/cid/civ298. PubMed PMID:
25900168; PubMed Central PMCID: PMC4565995.
9.   Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, et al. Serotypes of
Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.
JAMA. 2001;285(1):47-51. doi: 10.1001/jama.285.1.47. PubMed PMID: 11150108.
10.   Ardizzone CM, Albritton HL, Lillis RA, Bagnetto CEL, Shen L, Cavacini LA, et al.
Human genital antibody-mediated inhibition of Chlamydia trachomatis infection and
evidence for ompA genotype-specific neutralization. PLoS One. 2021;16(10):e0258759.
Epub 20211018. doi: 10.1371/journal.pone.0258759. PubMed PMID: 34662351;
PubMed Central PMCID: PMC8523062.
11.   van Bergen J, Hoenderboom BM, David S, Deug F, Heijne JCM, van Aar F, et al.
Where to go to in chlamydia control? From infection control towards infectious disease

control. Sex Transm Infect. 2021;97(7):501-6. Epub 20210527. doi: 10.1136/sextrans-
2021-054992. PubMed PMID: 34045364; PubMed Central PMCID: PMC8543211.
284

Figure 1. MLST sequence types (ST) and *ompA* genovars in CT isolates from AGYW from

Cape Town and Johannesburg. (A) Percentage distribution of MLST STs by region. Each

stacked bar represents the proportion of detected STs in Johannesburg and Cape Town.

*indicate STs that were unique to each region. (B) Minimum-spanning tree analysis of the

identified MLST STs, showing the genetic relationships between STs across regions. The

size of the nodes represents the frequency of the sequence type, while connecting lines

indicate isolates differing at a single locus. Colours correspond to geographic locations (Cape

Town shaded in green and Johannesburg in red). (C) Distribution of *ompA* genovars,

stratified by geographic location.

Figure 2. Transition in CT infection status over time in AGYW from Cape Town. (A)

Longitudinal changes in CT infection status across three study visits. Participants were

categorized based on their infection status at each visit (CT negative [green]; incident [blue],

cleared [visit 2: lilac or visit 3: purple], persisted [dark peach] or recurred [light orange]. (B)

Comparison of MLST STs identified at multiple visits in AGYW with recurrent infections.

The data illustrate whether recurrent infections were associated with the same ST (suggesting

persistence or reinfection by untreated partners) or different STs (indicating new infections).

Supplementary Table 1. Characteristics for women enrolled in the WISH study

Characteristics	All women (n=298)	Johannesburg (n=149)	Cape Town Visit 1 (n=149)	Cape Town Visit 2 (n=128)	Cape Town Visit 3 (n=93)	p-value*
Age	18 (17-20)	18 (17-20)	18 (17-20)	-	-	ns
Age of sexual debut	16 (15-17)	16 (16-17)	16 (15-17)	-	-	ns
Lifetime # partners	2 (1-13)	2 (1-10)	2 (1-13)	-	-	ns
Condoms (always)	69/267 (25.8%)	49/138 (36%)	20/129 (16%)	-	-	0.0002
Condoms (last sex)	190/267 (71.2%)	94/138 (68%)	96/129 (74%)	-	-	ns
Sex w HIV+ partner	20/267 (7.5%)	7/138 (5%)	13/129 (10%)	-	-	ns
Transactional sex	1/267 (0.4%)	0/138 (0%)	1/129 (1%)	-	-	ns
Contraceptives	284/298 (95.3%)	135/149 (90.6%)	149/149 (100%)			<0.0001
Ever pregnant	64/267 (24%)	30/138 (22%)	34/129 (26%)	-	-	ns
Anal sex (ever)	11/267 (4.1%)	3/139 (2%)	8/129 (6%)	-	-	ns
STI frequency:						
Any STI	221/298 (74.2%)	101/149 (67.8%)	120/149 (80.5%)	97/128 (75.8%)	70/93 (75.3%)	0.02
C. trachomatis	88/298 (29.5%)	26/149 (17.4%)	62/149 (41.6%)	43/127 (33.9%)	16/88 (18.2%)	<0.0001
N. gonorrhoea	24/298 (8.1%)	7/149 (4.7%)	17/149 (11.4%)	8/127 (6.3%)	7/88 (7.9%)	0.05
T. vaginalis	16/298 (5.4%)	5/149 (3.4%)	11/149 (7.4%)	10/127 (7.9%)	6/88 (6.8%)	ns
M. genitalium	11/298 (3.7%)	5/149 (3.4%)	6/149 (4.0%)	7/127 (5.5%)	6/88 (6.8%)	ns
Multiple STIs	30/298 (10.1%)	6/143 (4.0%)	24/149 (16.1%)	44/128 (34.4%)	23/88 (26.1%)	0.001
BV (Nugent 7-10)	135/292 (46.2%)	64/144 (44.4%)	71/148 (48.0%)	62/126 (49.2%)	39/84 (46.4%)	ns
Any STIs+BV	111/298 (37.2%)	51/149 (34.2%)	60/149 (40.3%)	46/128 (35.9%)	31/93 (33.3%)	ns

*Fisher's Exact test

A

Figure 1A

B

Figure 1B

Figure 1C

B

V1	V2	V3
169b	135b*	
559		559
62a	62a	
62a	62a	
	530b	530b
268a	268a	268a
3	3	3
551	551	551
530b	530b	530b
530b	530b	
553	530c*	554a*
528b	528b	188b
188b	188b	188b
12d	12d	
12d	12d	12d
12d		12d
188b		188b
12d		12d
319		137
85	85	85
12d	12d	
3	3	
555	555	
87	87	
556	556	
12d	3	
3	3	
100b	100b	
56a	56a	
530b	530b	

Figure 2B